Valorem Reply recognized as Winner of 2025 Microsoft Inclusion Changemaker Partner of the Year
12.11.2025 21:30:00 CET | Business Wire | Press Release
Valorem Reply, the Reply Group company specializing in Microsoft technologies and AI-driven, cloud-native solutions, announced today it has won the 2025 Microsoft Inclusion Changemaker Partner of the Year Award. The company was honored among a global field of top Microsoft partners for demonstrating excellence in innovation and implementation of customer solutions based on Microsoft technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112917859/en/
The Inclusion Changemaker Partner of the Year Award celebrates partners that lead with inclusive design, accessibility, and innovation to help customers and communities achieve more.
“We’re proud of Valorem Reply for earning this recognition,” said Filippo Rizzante, CTO at Reply. “Their work exemplifies our shared commitment to inclusion and to using technology as a catalyst for opportunity and meaningful change. This award reflects the dedication and creativity of the Valorem Reply team, who continue to demonstrate how innovation and inclusivity can come together to make a lasting impact and how technology can be harnessed for social good.”
The Microsoft Partner of the Year Awards recognize Microsoft partners that have developed and delivered outstanding Microsoft Cloud applications, services, devices, and AI innovation during the past year. Awards were classified in various categories, with honorees chosen from more than 4,600 nominations across more than 100 countries. Valorem Reply was recognized for providing outstanding solutions and services in the Inclusion Changemaker Partner of the Year Award category.
The Inclusion Changemaker Partner of the Year Award celebrates partners that lead with inclusive design, accessibility, and innovation to help customers and communities achieve more. Valorem Reply was recognized for its ability to advance digital equity and create measurable impact through inclusive solutions powered by Microsoft technologies. Valorem Reply was also named the Nonprofit Microsoft Partner of the Year in 2024.
Among its standout initiatives is the creation of a digital twin of St. Peter’s Basilica, developed in collaboration with Microsoft, Iconem and Sagepath Reply, which leverages AI and immersive 3D visualization to preserve cultural heritage and make one of the world’s most iconic landmarks accessible to audiences everywhere.
“Congratulations to all the winners and finalists of the 2025 Microsoft Partner of the Year Awards,” said Nicole Dezen, Chief Partner Officer and Corporate Vice President at Microsoft. “This year, our partners harnessed the transformative power of Microsoft’s Cloud and AI platforms to deliver transformative solutions that redefine the boundaries of innovation. The energy and ingenuity across our ecosystem continue to inspire us. The 2025 honorees exemplify what’s possible when technology and vision unite to empower customers around the world.”
In addition to being named the Inclusion Changemaker Partner of the Year, Reply was also recognized as the Americas SI Emerging Partner of the Year, thanks to Root16 Reply, a company specializing in Microsoft CRM consulting and system integration.
The 2025 Microsoft Partner of the Year Awards are announced ahead of Microsoft Ignite, which will be held in San Francisco from November 18–21. Additional details on the 2025 awards are available on the Microsoft Partner blog: https://aka.ms/2025POTYA_Announcement. The complete list of categories, winners and finalists can be found at https://aka.ms/2025POTYAWinnersFinalists.
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply supports major industrial groups in the telecom and media; industry and services; banking and insurance and public sectors in defining and developing business models enabled by the new paradigms of AI, cloud computing, digital media and the internet of things. Reply's services include: consulting, system integration and digital services. www.reply.com
Valorem Reply
Valorem Reply, part of the Reply group, is a prioritized Microsoft Cloud Solutions Partner focused on transforming businesses into intelligent enterprises and helping nonprofits achieve more with AI enabled, cloud native solutions, strategic business outcome focus and user-led design. Through our teams of elite practitioners, our passion for doing good and the power of Microsoft technologies, we securely and rapidly transform the way our clients do business. valoremreply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112917859/en/
Contacts
Media contact
Reply
Fabio Zappelli
f.zappelli@reply.com
Phone +390117711594
Irene Caia
i.caia@reply.com
Tel. +39 02 535761
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom